Disease · EFO_0009130
clostridium difficile infection
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. clostridium difficile infection. Diseases, record EFO_0009130. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009130
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- clostridium difficile infection
- Open Targets ID
- EFO_0009130
- Other names
- CDI, clostridium difficile disease
- Highest stage of its drugs
- Approval, for 2 of its 14 drugs, from DailyMed, FDA and PMDA
Source Open Targets
Drugs14
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BEZLOTOXUMAB | CHEMBL2108670 | Antibody | Approval | DailyMed and PMDA | 5 | 3 | 3 | Drugs and targets |
| FECAL MICROBIOTA SPORES, LIVE | CHEMBL6068500 | Approval | FDA | 1 | 0 | 0 | Drugs and targets | |
| VANCOMYCIN | CHEMBL262777 | Small molecule | Phase 3 | ClinicalTrials.gov | 21 | 21 | 21 | Drugs and targets |
| FIDAXOMICIN | CHEMBL1255800 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| METRONIDAZOLE | CHEMBL137 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| CADAZOLID | CHEMBL3707376 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| SUROTOMYCIN | CHEMBL2375161 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TOLEVAMER POTASSIUM SODIUM | CHEMBL2108655 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| NITAZOXANIDE | CHEMBL1401 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| POLYETHYLENE GLYCOL | CHEMBL1201478 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 14
See all 14 drugsTargets0
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
None in this release.
Trials39
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01983683 | Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea | Phase 3 | 631 | 2018-04-13 | Clostridium Difficile Infection | CADAZOLID, VANCOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT01597505 | Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) | Phase 3 | 606 | 2018-02-28 | Clostridium Difficile Infection | SUROTOMYCIN, VANCOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT01085591 | Study of CB-183,315 in Participants With Clostridium Difficile Infection | Phase 2 | 210 | 2015-06-16 | Clostridium Difficile Infection, Diarrhea | SUROTOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT03182907 | Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001) | Phase 3 | 148 | 2023-06-07 | Clostridium Difficile Infection | BEZLOTOXUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02395848 | Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection | Phase 3 | 31 | 2023-03-24 | Clostridium Difficile Infection | FIDAXOMICIN | Its record names the disease | ClinicalTrials.gov |
| NCT00304356 | Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection | Phase 3 | 22 | 2017-12-15 | Clostridium Enterocolitis, Pseudomembranous Colitis | NITAZOXANIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02053350 | Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection | Phase 2 | 7 | 2022-06-07 | Clostridium Difficile Infection | GLUTAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT03760484 | Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection | Phase 2 | 4 | 2022-12-13 | Clostridium Difficile | FIDAXOMICIN | Its record names the disease | ClinicalTrials.gov |
| NCT03617445 | Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients | Phase 2 | 3 | 2025-01-09 | Clostridium Difficile Infection Recurrence | VANCOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT01346059 | Intracolonic Vancomycin Therapy in Severe C. Diff Colitis | Not applicable | 2 | 2017-03-29 | Colitis | VANCOMYCIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 39
See all 39 trialsComparisons in its trials8
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cadazolid vs Vancomycin: deaths from any cause | 11 of 294 | 15 of 307 | 601 | NCT01983683 | Trial comparisons |
| Cadazolid vs Vancomycin: serious adverse events | 35 of 294 | 46 of 307 | 601 | NCT01983683 | Trial comparisons |
| Surotomycin vs Vancomycin: deaths from any cause | 18 of 305 | 9 of 286 | 591 | NCT01597505 | Trial comparisons |
| Surotomycin vs Vancomycin: serious adverse events | 44 of 305 | 37 of 286 | 591 | NCT01597505 | Trial comparisons |
| Bezlotoxumab vs Placebo: deaths from any cause | 6 of 111 | 1 of 37 | 148 | NCT03182907 | Trial comparisons |
| Bezlotoxumab vs Placebo: serious adverse events | 57 of 107 | 29 of 36 | 143 | NCT03182907 | Trial comparisons |
| Saline vs Vancomycin: deaths from any cause | 0 of 1 | 0 of 1 | 2 | NCT01346059 | Trial comparisons |
| Saline vs Vancomycin: serious adverse events | 0 of 1 | 0 of 1 | 2 | NCT01346059 | Trial comparisons |
Papers from its trials41
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0009130
GET https://conductscience.org/api/diseases/v1/EFO_0009130/trials?page=2